N-methyl-D-aspartate (NMDA) glutamate receptor antagonists are used in clinical anesthesia and are being developed as therapeutic agents for preventing neurodegeneration in stroke, epilepsy, and brain...
Oxidative stress has been implicated in the pathogenesis of several neurodegenerative diseases and may result from excessive free radical production due to increased local metabolism. Non-competitive N-methyl-D-aspartate (NMDA)...
Hughes AM, Rhodes J, Fisher G, Sellers M, Growcott JW. British Journal of Clinical Pharmacology 2002 Jun;53(6):604-612.
AIMS: The aim of this study was to assess the efficacy of dextromethorphan and ketamine relative to placebo on the acute nociceptive threshold and wind-up of second pain...
Submitted by Paracelsus
21-10-2007
97.60 Kbytes
Hits 53
Keywords: dxm
Stroke. 1996;27:743-746.
Roland N. Auer, MD, PhD
BACKGROUND AND PURPOSE: Although N-methyl-D-aspartate (NMDA) antagonism may be a useful therapeutic approach in stroke treatment, it has been found that these pharmacological agents cause neuronal necrosis in restricted cortical regions of...
Recent studies have shown that several compounds known to act as competitive or non-competitive antagonists of NMDA receptors can disrupt learning in rodents. The present study was carried out to investigate the effects of a range of...
Abstract:
Single doses of an NMDA antagonist cause an adult or a prepubertal form of neurodegeneration, depending on the age of the animal. Single doses of ethanol (EtOH) by blocking NMDA receptors...
Submitted by Salvinorin A
15-01-2010
408.70 Kbytes
Hits 12
Brain Research 993 (2003) 90–100
Nuri B. Farber, Xiaoping Jiang, Krikor Dikranian, Brian Nemmers
N-Methyl-D-aspartate (NMDA) glutamate receptor antagonists are being developed as therapeutic agents for several clinical conditions. However, the ability of these agents to produce...
Ma D, Wilhelm S, Maze M, Franks NP. British Journal of Anaesthesia 2002;89(5):739-46.
BACKGROUND: Antagonists of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors have been shown not only to have neuroprotective effects but also to exhibit neurotoxic properties. In this study, we...
Submitted by Paracelsus
13-11-2007
329.23 Kbytes
Hits 91
Shin EJ, Lee PH, Kim HJ, Nabeshima T, Kim HC. Journal of Pharmacological Sciences 2008 Jan;106(1):22-7.
Drug abuse involving dextromethorphan, an antitussive, has been a social problem in various geographic locations since the 1960s. Ironically, high doses of the drug confer neuroprotective...
Submitted by ThirdEyeFloond
21-01-2008
455.74 Kbytes
Hits 51
Keywords: dxm
The Journal of Neuroscience, April 15, 2002, 22(8):3070–3080
Qiang Li, Suzanne Clark, Darrell V. Lewis, and Wilkie A. Wilson
NMDA receptor antagonists produce region-specific neurodegeneration by an undetermined mechanism, but one proposed mechanism involves disinhibition. In certain areas...
Wellon D. Collom and Charles L. Winek
Clinical Toxicology: 1968, Vol. 1, No. 3, Pages 309-317 , DOI 10.3109/15563656808990584
Submitted by nnizzle
13-05-2010
602.21 Kbytes
Hits 2
The Journal of Neuroscience, January 1988, 8(1): 165-196
Dennis W. Choi, Jae-young Koh, and Stephen Peters
The antagonist pharmacology of glutamate neurotoxicity was quantitatively examined in murine cortical cell cultures. Addition of 1-3 mM DL-2-amino-5-phosphonovalerate (APV), or its...
Vesna Jevtovic-Todorovica, David F. Wozniakb, Sarah Powell and John W. Olney
N-Methyl-D-aspartate (NMDA) antagonists act by an anti-excitotoxic action to provide neuroprotection against acute brain injury, but these agents can also cause toxic effects. In...
NB Farber, SH Kim, K Dikranian, XP Jiang and C Heinkel
NMDA glutamate receptor antagonists are used in clinical anesthesia, and are being developed as therapeutic agents for preventing neurodegeneration in stroke, epilepsy, and brain trauma. However, the...
Journal of Pharmacology and Experimental Therapeutics 2002 May;301(2):690-7
Winger G, Hursh SR, Casey KL, Woods JH.
The potential contribution of onset and duration of pharmacological action to the reinforcing strength of three intravenously delivered N-methyl-D-aspartate antagonists was...
Submitted by Jatelka
06-07-2008
122.61 Kbytes
Hits 29
Hypofunction of the N-methyl-D-aspartate receptor (NMDAR) may be involved in the pathophysiology of schizophrenia. NMDAR
antagonists like ketamine induce schizophrenia-like features in...
Submitted by Paracelsus
05-11-2007
151.32 Kbytes
Hits 42
Phencyclidine, ketamine, and other agents that block NMDA glutamate receptors trigger a schizophrenia-like psychosis in humans and induce pathomorphological changes in cerebrocortical...